Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data
British Journal of Clinical Pharmacology · 2025
DOI: 10.1002/bcp.70143 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Zhekang Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular medicine, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital, Jiujiang, Jiangxi, China. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Anemia, Hydroxymethylglutaryl CoA Reductases. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Key Research and Development Project of Jiujiang Science and Technology Bureau.
Abstract (Originalsprache)
Aims
Statins are widely used for managing dyslipidaemia and preventing cardiovascular events. Reports on whether statin use and anaemia are associated are scarce and controversial. The relationship between statins and anaemia remains unclear. This study aimed to explore the potential causal link between statin use and anaemia.
Methods
We employed a two‐sample Mendelian randomization (MR) approach using single nucleotide polymorphisms related to HMGCR expression, the gene targeted by statins, to evaluate the causal effect of statin use on anaemia. Genome‐wide association study data specific to European populations were used to identify genetic associations, and clinical data from National Health and Nutrition Examination Survey (NHANES; 2005–2016) were analysed to validate the MR findings. Logistic regression models were used to assess the association between statin use and anaemia risk in the NHANES cohort.
Results
MR analysis indicated that upregulation of HMGCR expression was associated with a reduced risk of anaemia (odds ratio = 0.72, 95% confidence interval 0.58–0.88; P = .007). In contrast, the analysis of NHANES data revealed that statin use was significantly associated with an increased risk of anaemia (odds ratio = 1.624, 95% confidence interval 1.307, 2.018; P < .001). Sensitivity analyses revealed the reliability of the MR results, and the association between statin use and anaemia was further supported by the consistency of univariate and multivariate regressions in NHANES.
Conclusions
Our findings suggest that while genetic up‐regulation of HMGCR may reduce anaemia risk, statin therapy is associated with an increased risk of anaemia. These results highlight the need for careful monitoring of haemoglobin and iron levels in patients undergoing long‐term statin treatment, especially those with pre‐existing risk factors for anaemia. Further research is necessary to elucidate the underlying mechanisms and to confirm these findings in diverse populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular medicine, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital, Jiujiang, Jiangxi, China.
- The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
- Cardiovascular medicine department, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
ORCID-Profile: Junda Cao
Förderung
- Key Research and Development Project of Jiujiang Science and Technology Bureau
Zitieren
APA
Liu, Z., Fu, Q., & Cao, J. (2025). Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70143
Vancouver
Liu Z, Fu Q, Cao J. Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70143
BibTeX
@article{Liu2025,
author = {Liu, Zhekang and Fu, Qingan and Cao, Junda},
title = {Statins as a risk factor for anaemia: Evidence from genetic and epidemiological data},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
doi = {10.1002/bcp.70143}
}
EUVIMED